Arena Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical study of ralinepag, a receptor agonist for non-prostanoid prostacyclin (IP) intended for the treatment of pulmonary arterial hypertension (PAH). The case-control study, randomized double-blind trial will last 22 weeks and will evaluate the hemodynamic effects, safety and tolerability of ralinepag on up to 60 patients with PAH. PAH is a progressive disease that can lead to heart failure and reduce life expectancy. Based on US data, it is estimated that the five-year survival from diagnosis of the disease is 57%. Ralinepag, orally available, in the phase 1 studies showed half-life of about 25 hours and was therefore suitable for one or two doses per day. The FDA has granted orphan drug status for the treatment of PAH.


Please enter your comment!
Please enter your name here